Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MobilEye Global Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while MobilEye Global Inc trades at $9.48 (market cap $8.04B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5× MobilEye Global Inc's market cap, and MobilEye Global Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MBLY | |
|---|---|---|
Market Cap | $39.89B | $8.04B |
Sector | Health | Technology |
52-Week High | $491.22 | $16.57 |
52-Week Low | $278.09 | $6.56 |
Enterprise Value | $38.15B | $6.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Mobileye (MBLY) trades at $9.55, up 0.21% with a bullish technical signal. The company shows strong revenue growth ($1.89B in 2025) but significant net losses (-$392M). Recent earnings beat expectations in Q1 2026, while analysts maintain a 57.69% buy rating with a $10.36 consensus target. The stock faces pressure from negative profitability metrics but benefits from positive sentiment around its 2027 robotaxi launch plans.
MBLY presents a high-risk opportunity with transformative potential through autonomous driving technology. The upcoming robotaxi business could drive long-term growth, but current financial losses and competitive pressures require careful monitoring. Investor sentiment remains cautiously optimistic pending execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
